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Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the
past four decades; however, preliminary clinical data indicate that lenvatinib may provide
efficacy benefits for patients with ATC. This real-world study aimed to define the potential
role of lenvatinib in ATC by examining the impact of treatment administered alongside
existing therapies.
Methods: This was a retrospective, single-center analysis of Korean patients with
confirmed ATC who received lenvatinib between October 2015 and February 2018.
Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years;
61.1% female). Six [33.3%] had resectable disease that progressed after a combination
of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease
that progressed after radiation treatment and chemotherapy. Study endpoints were
overall survival (OS) and change in volume of the largest tumor assessed via imaging.
Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64–839
days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three
patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had
local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor
volume increases of 9–10%. The other 16 patients (88.9%) had tumor volume reductions
of 2–69%. Six patients (33.3%) had tumor volume reductions ≥50%.
Conclusions: In patients with ATC who had progressed on prior therapy, addition of
lenvatinib could improve survival duration and reduce tumor volume. Further studies of
lenvatinib in ATC are warranted.
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INTRODUCTION
Anaplastic thyroid cancer (ATC) is a rare, highly aggressive
malignancy composed of undifferentiated thyroid follicular cells
(1). It is a devastating disease that carries a very poor prognosis
(2). ATC accounts for ∼2% of all thyroid neoplasms, but is
responsible for up to 50% of thyroid cancer mortality (3). In
addition to local invasion, ATC often metastasizes to regional
lymph nodes and distant sites (4).
A recent analysis of the Surveillance, Epidemiology, and End
Results (SEER) database suggested that the incidence of ATCmay
be increasing (5), which is likely caused by increased detection
of tumors due to improved diagnosis guidelines. There were
1,527 patients diagnosed with ATC between 1973 and 2014;
in 1973 the age-adjusted incidence rate was 0.2 per 1,000,000
people, compared with a rate of 1.2 per 1,000,000 in 2014.
This corresponds to an average annual percentage increase of
3.0% (5). Median survival with ATC is reported to be around
5 months, with fewer than 20% of patients surviving for more
than 1 year (6). Survival rates have not improved in the past
four decades despite considerable research and the availability
of new treatments (5). Analysis of SEER data indicated that
the median disease-specific survival time was 4 months during
the period of 2010–2014, which was almost unchanged from
the median 3-month survival time during the period of
1975–1979 (5).
Current treatment guidelines for ATC suggest that therapy
should include surgery for resectable disease, locoregional
radiotherapy, and systemic chemotherapy (adjuvant or second-
line) (7, 8). Targeted agents such as the B-Raf inhibitor
dabrafenib, the mitogen-activated protein kinase (MAPK)
inhibitor trametinib, and the tropomyosin receptor kinase
(TRK) inhibitor larotrectinib may be useful in patients with
specific genetic mutations (7). The multitargeted tyrosine kinase
inhibitor (TKI) lenvatinib is currently recommended for use in
patients without curative options who have no response to other
agents (7).
Lenvatinib was approved as a monotherapy for the treatment
of differentiated thyroid cancer (2015), in combination with
everolimus for the treatment of advanced renal cell carcinoma
(2016) andmost recently as a first-line treatment for unresectable
hepatocellular carcinoma (2019) (9–12). Preliminary clinical data
also suggest that lenvatinib may provide efficacy benefits for
patients with ATC (10, 13, 14). In a phase 2, single-arm, open-
label study in 17 patients with ATC, the median progression-free
survival was 7.4 months, the median overall survival (OS) was
10.6 months, and the objective response rate was 24%. Although
all patients reported treatment-emergent adverse events (AEs),
the majority were manageable with dose adjustments (10, 13, 14).
As of yet, however, there is no established protocol for the
treatment of patients with ATC, and lenvatinib’s place in the
treatment algorithm is unclear.
This retrospective, real-world analysis was conducted to
examine the impact of lenvatinib when administered alongside
existing local and systemic treatments to further define the
potential role of this agent in improving outcomes for patients
who have few other treatment options.
MATERIALS AND METHODS
Study Design
This was a retrospective, single-center analysis of patients with
confirmed ATC (diagnosed between January 2008 and December
2017) who received lenvatinib treatment at the Gangnam
Severance Hospital (Seoul, South Korea) between October 2015
and February 2018. For eligible patients, electronic medical
records were reviewed to extract data on clinical characteristics,
including age, tumor characteristics, prior treatment, and
treatment outcomes.
All procedures involving patients were performed in
accordance with the ethical standards of institutional regulations
and all applicable local/national regulations, and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards. In accordance with the Bioethics and Safety
Act of Korea, formal consent was not required for this type of
retrospective, observational analysis.
Patients
Patients with confirmed ATC who received treatment
with lenvatinib after progression with previous anticancer
therapy were eligible for inclusion in the analysis. Pathologic
confirmation of ATC was required to confirm the diagnosis of
ATC, either through surgery or via open biopsy or core needle
biopsy. Patients who had received treatment with sorafenib were
excluded. No additional exclusion criteria were applied. Patients
were followed up for at least 1 year or until death occurred.
Treatment
Lenvatinib was added to each patient’s existing treatment. The
treatment protocol followed in our hospital for patients with ATC
is shown in Figure 1. Administration of symptomatic therapy
was allowed for patients who experienced treatment side effects.
Surgery was planned for patients in whom the primary tumor
was resectable and there was no distant metastasis. The patient
was administered one cycle of paclitaxel (one injection of 70
mg/m2 each week for 3 weeks followed by a break of 1 week, with
concomitant intensity-modulated radiation therapy [IMRT] at a
dose of 3,960 cGy). After 6 weeks, tumor imaging (using positron
emission tomography [PET], computed tomography [CT], or
magnetic resonance imaging [MRI]) was used to determine
whether surgery was appropriate. One further cycle of paclitaxel
(70 mg/m2) plus IMRT (2,640 cGy) was administered prior to
surgery, and three cycles of paclitaxel (without IMRT) were
administered post-surgery. Routine diagnosis was conducted
every two cycles, and if progression was observed, lenvatinib
10 mg/day was added to the treatment regimen. The maximum
number of post-surgical paclitaxel cycles was six per patient.
In patients who were judged to have unresectable disease
after the first 6 weeks, paclitaxel chemotherapy and IMRT were
continued, with routine imaging performed every two cycles.
If progression occurred, lenvatinib 10 mg/day was added. If
progression continued, the dose of lenvatinib could be increased
to 20 mg/day, and finally to 24 mg/day. The starting dose of
lenvatinib was 10 mg/day, as clinical experience has shown that
numerous adverse events, including leukopenia and generalized
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FIGURE 1 | Anaplastic thyroid cancer treatment protocol followed at the Gangnam Severance Hospital.
muscle weakness, were reported when starting with a maximum
dose of lenvatinib in a combination therapy.
Efficacy Outcomes
The primary study endpoint was OS, defined as the duration
between the start of lenvatinib treatment until death from any
cause. Survival rates at 6 months and 1 year were also calculated.
The secondary endpoint was change in volume of the largest
tumor (primary or metastasis) assessed using PET, CT, or MRI.
Statistical Methods
As far as possible, all patients who received lenvatinib treatment
in our institute between October 2015 and February 2018 were
enrolled in the study; the only exclusions were for prior treatment
with sorafenib. No sample size estimations or power calculations
were performed.
For the analysis of study data, categorical variables were
described by frequency and proportion; summary statistics
(median, range) were used to report continuous data. Survival
curves were generated using the Kaplan–Meier method based on
the log-rank test. As this was a retrospective analysis, no formal
statistical comparisons were performed.
RESULTS
Patients
The patient disposition is shown in Figure 2. A total of 74
patients with ATC were evaluated, of whom 53 were not treated
with a TKI. Of the 21 patients who received TKI treatment, three
received sorafenib; 18 patients received lenvatinib and formed the
analysis population.
Patient demographics and disease characteristics are described
in Table 1. The mean age was 64.9 years, 61.1% of patients
were female, the majority of patients (77.8%) had an Eastern
Cooperative Oncology Group performance score (ECOG PS) of
0, and 94.5% had stage IVC ATC at diagnosis.
Lenvatinib was administered to patients with resectable
disease (n = 6 [33.3%]) that had progressed after a combination
of surgery, radiotherapy, and chemotherapy, and to patients
with unresectable disease (n = 12 [66.7%]) that had progressed
after radiation treatment and chemotherapy. All patients (100%)
had received radiation therapy and paclitaxel prior to starting
lenvatinib. Detailed treatment data for individual patients are
provided in Supplementary Material Table S1. The treatment
timeline is shown in Supplementary Material Table S2.
Primary Outcome
The median OS for the 18 patients who received lenvatinib was
230 days (range 64–839 days) (Table 1). Survival rates were 61.1%
at 6 months and 22.2% at 1 year (Figure 3). Three patients
(16.7%) survived beyond 1 year with lenvatinib treatment. Of
the 15 patients who died, four (26.7%) had local disease and 11
(73.3%) had distant metastasis.
Secondary Outcome
The percent change from baseline in the volume of the largest
tumor (metastasis or primary) during lenvatinib treatment is
shown in Figure 4. Two patients (11.1%) had increases in tumor
volume of 9–10%. The other 16 patients (88.9%) had reductions
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FIGURE 2 | Patient disposition. TKI, tyrosine kinase inhibitor.
TABLE 1 | Patient characteristics and clinical features.
Variable Patients
N = 18
Age (years), mean ± SD (range) 64.9 ± 11.1 (42–86)
Male: female ratio, n (%) 7 (38.9):11 (61.1)








Tumor size (cm), mean ± SD
Baseline 5.2 ± 1.6
Post-therapy 3.5 ± 2.0
Combined therapy, n (%)
Surgery 6 (33.3)
Chemotherapy 18 (100)
External radiation 18 (100)
Survival time (days), median (range) 230 (64–839)
Survival rate, n (%)
6 months 11 (61.1)
1 year 4 (22.2)
>1 year 3 (16.7)
Patients who died, n (%) 15 (83.3)
Local disease 4 (26.7)
Distant metastasis 11 (73.3)
ECOG PS, Eastern Cooperative Oncology Group performance score; SD,
standard deviation.
in tumor volume from 2 to 69%. Six patients (33.3%) had tumor
volume reductions ≥50%.
DISCUSSION
This retrospective analysis evaluated the role of the TKI
lenvatinib in the treatment of patients with ATC, a disease with
a poor prognosis. Despite the use of aggressive therapy, median
survival has not changed significantly in several decades (15).
Current survival times for patients with ATC are reported to be
extremely short and median OS for patients with unresectable
disease ranges from 0.5 to 6 months despite multimodal
treatment (16–18).
The key finding of this study is that the median OS (∼8
months) using our treatment regimen was improved compared
with historical OS rates for currently available therapies.
Furthermore, tumor volume decreased by ≥50% in 33% of
patients, and showed at least some reduction in 88.9% of the
patients receiving lenvatinib. These results, in patients who had
progressed on their existing treatment, suggest that the addition
of lenvatinib can provide benefit even to patients with advanced
disease who otherwise have few treatment options.
In recent years, the focus of cancer research has turned to
molecular targeted therapies, and in ATC the most promising
new treatment options appear to be multitargeted TKIs (1,
19, 20). However, although early stage studies have reported
encouraging results, phase 3 data are lacking, and the place of
these treatment agents within the therapeutic algorithm remains
unclear. Retrospective data can be used to bridge the current
knowledge gap, and provide much-needed data for clinicians
looking to improve outcomes for their patients. Previous
retrospective analyses in Japanese patients have indicated that
Frontiers in Endocrinology | www.frontiersin.org 4 September 2020 | Volume 11 | Article 599
Kim et al. Lenvatinib in Anaplastic Thyroid Cancer
lenvatinib is associated with disease control rates (clinical
response or stable disease) of 44% (21) to 100% (22), and OS
times of 165 (22) to 166 (21) days, although tumor volumes
were not evaluated. While it is not possible to directly compare
studies due to the heterogeneity of the enrolled patients and
the differing therapeutic procedures used, the treatment regimen
used in our institute was able to produce a relatively lengthy
median OS of 230 days, and additionally demonstrated a
direct, measurable impact on tumor volume in almost 90%
of patients.
FIGURE 3 | Survival rates of anaplastic thyroid cancer patients treated with
lenvatinib.
A recent phase 2 study of lenvatinib treatment in patients
with ATC reported a median OS of 10.6 months and some
degree of tumor shrinkage (10, 14). The results of our analysis
support these clinical study data and confirm the hypothesis
that lenvatinib should be considered earlier in the treatment
regimen. Currently, there is no established protocol for the
use of lenvatinib in patients with ATC. Our data suggest that
the addition of lenvatinib to existing anticancer drugs may
increase the sensitivity to treatment; this confirms previous
non-clinical research which suggested synergistic antineoplastic
activity resulting from the combined use of chemotherapy,
radiotherapy, and TKI inhibitors (23). However, the potential
for toxicity may also increase when combining several treatment
modalities; furthermore, AEs are commonly reported with TKI
treatment (24, 25). Nonetheless, these may be overcome through
dose adjustments (24, 25), and the benefit accorded to patients
through the early initiation of lenvatinib in combination with
other anticancer therapies may outweigh the potential risks.
Study Strengths and Limitations
This article presents important and novel data on the use
of lenvatinib to treat ATC, which have not been available
thus far. There is a clear unmet need for improved treatment
regimens for patients with ATC, who currently have a poor
prognosis and short survival times, and this analysis expands
the evidence base for clinicians considering the optimal therapy
for ATC. We recognize that in our study, patients were only
treated with lenvatinib following progression on paclitaxel and
IMRT. Although we hypothesize that introducing lenvatinib
into the treatment regimen at an earlier stage may help to
increase survival times, the burden on the patient must also be
considered. As such, optimal adjustment of the appropriate doses
of lenvatinib and paclitaxel will be critical.
FIGURE 4 | Change in volume of largest primary or metastatic tumor from the start to the end of lenvatinib treatment.
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We also acknowledge the study limitations of our analysis,
several of which are inherent to retrospective analyses. First,
this was an observational study, and the results were reliant on
the completeness and accuracy of the medical records used. In
addition, the lack of a control arm of patients who did not receive
lenvatinib treatment precludes direct comparisons; nonetheless,
historical comparisons with previously published studies suggest
the utility of lenvatinib in this setting. Second, data from this
single-center study require additional confirmation before they
can be extrapolated to the wider ATC population. Moreover,
as this study only included Korean patients, the generalizability
of the current findings may be limited. Finally, there was
no attempt made in this study to evaluate the type and
frequency of AEs related to lenvatinib therapy. ATC is a very
aggressive disease that causes multiple symptoms in patients. In
addition, AEs may be caused by paclitaxel or IMRT treatment.
Because this was a retrospective analysis of electronic medical
records, we were not able to investigate the association, if
any, between AEs and lenvatinib. Additional analyses will
be necessary to further elucidate the safety profile of this
treatment regimen.
Conclusions
The results of this analysis of patients with ATC who had
progressed on prior therapy suggest that the addition of
lenvatinib was able to improve survival duration and reduce
tumor volume. Further studies to evaluate lenvatinib in this
patient population are warranted.
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